Which depressions respond to placebo?

Area of Science:

• Psychiatry
• Clinical Psychology
• Neuroscience

Background:

• Understanding predictors of antidepressant treatment response is crucial for optimizing patient outcomes.
• Distinguishing placebo responders from nonresponders can inform clinical trial design and interpretation.

Purpose of the Study:

• To compare demographic, diagnostic, illness history, and symptomatic features between placebo responders and nonresponders in major depressive disorder.
• To identify characteristics associated with positive response to placebo in depression treatment.

Main Methods:

• A descriptive study involving 55 outpatients diagnosed with unipolar major depression.
• Comparison of 21 placebo responders versus 34 placebo nonresponders on various clinical and demographic variables.

Main Results:

• Placebo responders were more likely to have nonendogenous depression and comorbid diagnoses.
• Placebo responders reported shorter illness duration and lower self-rated depressive symptom severity (Beck Depression Inventory, Carroll Rating Scale).
• Clinician-rated symptom severity and demographic variables did not differentiate the groups.

Conclusions:

• Nonendogenous depression, comorbid diagnoses, shorter illness duration, and lower symptom burden may predict placebo response in major depressive disorder.
• These characteristics could serve as potential indicators for patient selection or stratification in antidepressant drug trials.